**APHASIA** 

IN

# IAP20 Rec'd PCT/PTO 22 JUN 2006 PATENT APPLICATION

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q95616

Hideki OHYAMA

Appln. No.: Based on PCT/JP04/019373

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: June 22, 2006

Examiner: Unknown

For: AGENT OR METHOD FOR TREATING SEVERE

CEREBROVASCULAR ACCIDENT CHRONIC STAGE

### <u>INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 C.F.R. §§ 1.97 and 1.98</u>

#### MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

10/584155 IAP20 Rec'd PCT/PTQ 22 JUN 2006

INFORMATION DISCLOSURE STATEMENT U.S. Appln. No.: Based on PCT/JP04/019373

Attorney Docket No.: Q95616

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant encloses herewith a copy of a Communication from a

foreign patent office in a counterpart application citing such documents (International Search

Report for PCT/JP04/019373 dated April 19, 2005), together with an English-language version

(if not already included) of at least that portion of the Communication indicating the degree of

relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: June 22, 2006

Mark Boland

Registration No. 32,197

# iAP20 Rec'd PCT/PTO 22 JUN 2006 MODIFIED PTO/SB/08 A & B (08-03)

Substitute for Form 1449 A & B/PTO

Sheet

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known			
Application Number	Based on PCT/JP04/019373		
Confirmation Number	Unknown / : .		
Filing Date	June 23, 1000 84 1.55		
First Named Inventor	Hideki OHYAMA		
Art Unit	Unknown		
Examiner Name	Unknown		
Attorney Docket Number	Q95616		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document		Publication Date MM-DD-YYYY	
		Number	Kind Code <sup>2</sup> (if known)		Name of Patentee or Applicant of Cited Document
	•	US			
		US			
	- 1.	US			
*		US			
		US			
		US			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation <sup>6</sup>
		JP	51-34151	Α	03-23-1976		
		+	,				<del></del>
		<del> </del>					
				-			<del></del>
		<del>-</del>					

Examiner Initials*	Cite No.1	and a second control of the control					
		J. KESSLER, et al., "Piracetam Improves Activated Blood Flow and Facilitates Rehabilitation of Poststroke Aphasic Patients", Stroke, 2000, pp. 2112-2116, Vol. 31					
		W. HUBER, et al., "The Role of Piracetam in the Treatment of Acute and Chronic Aphasia", Pharmacopsychiatry, 1999, pp. 38-43					
		International Search Report for PCT/JP04/019373 dated April 19, 2005					

Examiner Signature	Date Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.